PMC9951597_01
The 3rd day after intravenous immunoglobulin.
CCID-16-457-g0001.jpg
PMC9951597_01_CCID-16-457-g0001.jpg
f0001
The skin rashes developed sheet-like epidermal detachment and epidermal necrosis involving nearly 70% of the body surface area (Figure 1).
The 7th day after subcutaneous injection of adalimumab, AbbVie Inc. USA.
CCID-16-457-g0002.jpg
PMC9951597_01_CCID-16-457-g0002.jpg
f0002
The desquamation had occurred in part of the primary rashes (Figure 2).
The 35th day after subcutaneous injection of adalimumab, AbbVie Inc. USA.
CCID-16-457-g0003.jpg
PMC9951597_01_CCID-16-457-g0003.jpg
f0003
At the follow-up visit 45 days later, the majority of the skin lesions had disappeared (Figure 3).